Masayuki Hashiguchi
Overview
Explore the profile of Masayuki Hashiguchi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
422
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kido K, Shimizu M, Shiga T, Hashiguchi M
Ann Pharmacother
. 2025 Mar;
:10600280251325250.
PMID: 40088126
No abstract available.
2.
Yokohara S, Hashiguchi M, Shiga T
J Arrhythm
. 2023 Dec;
39(6):928-936.
PMID: 38045460
Background: Drug-induced life-threatening ventricular arrhythmias including torsade de pointes (TdP), ventricular tachycardia (VT), and ventricular fibrillation (VF) are serious cardiac side effects. Psychotherapeutic drugs are known to be risk factors...
3.
Kido K, Shimizu M, Shiga T, Hashiguchi M, Jalil B, Caccamo M, et al.
Am J Cardiol
. 2023 Oct;
210:172-176.
PMID: 37844719
No abstract available.
4.
Suzuki S, Imai S, Mitsuboshi S, Kizaki H, Hashiguchi M, Hori S
J Clin Pharmacol
. 2023 Jul;
63(10):1171.
PMID: 37515403
No abstract available.
5.
Kido K, Bianco C, Caccamo M, Hashiguchi M, Choo L, Sokos G
J Pharm Pract
. 2023 May;
37(3):708-711.
PMID: 37191352
There is no standard approach for managing the use or dose of loop diuretics after initiating sacubitril/valsartan. To investigate longitudinal trends in loop diuretic therapy use and doses during the...
6.
Chatani R, Kondo S, Kamimura T, Suzuki S, Komatsubara E, Hayashi S, et al.
J Clin Pharmacol
. 2023 Apr;
63(9):1002-1008.
PMID: 37114401
Hypersensitivity reactions induced by nonionic iodine contrast media sometimes occur and can be life threatening. However, independent factors affecting their occurrence remain to be fully established. Therefore, the purpose of...
7.
Suzuki S, Imai S, Mitsuboshi S, Kizaki H, Hashiguchi M, Hori S
J Clin Pharmacol
. 2023 Apr;
63(8):903-908.
PMID: 37042319
The usefulness of disproportionality analysis for the pharmacovigilance of vaccines in the Japanese Adverse Drug Event Report (JADER) database is yet to be proven. This study aimed to verify whether...
8.
Kido K, Kabulski G, Szymanski T, Shiga T, Shimizu M, Hashiguchi M
J Pharm Pract
. 2022 Nov;
37(2):429-434.
PMID: 36449392
Unfractionated heparin (UFH) has traditionally been the agent of choice in patients on extracorporeal membrane oxygenation (ECMO). However, direct thrombin inhibitors (DTI) have recently garnered more attention in ECMO because...
9.
Okada T, Hashiguchi M, Hori S
Int J Clin Pharm
. 2022 Sep;
44(6):1332-1341.
PMID: 36156764
Background: Signal detection in reports of spontaneous adverse drug reactions is useful in pharmacovigilance, but does not adequately consider potential confounding factors such as patient background information contained in the...
10.
Shimizu M, Furudate S, Nagai Y, Shimada K, Ohshima M, Setoguchi K, et al.
Mod Rheumatol
. 2022 Sep;
33(5):953-960.
PMID: 36112484
Objectives: Reduction of the hydroxychloroquine (HCQ) dosage is recommended in systemic lupus erythematosus (SLE) patients with renal impairment, but a pharmacokinetics (PK) study of patients with renal impairment has not...